Rights and permissions
About this article
Cite this article
CQA 206291: has antiparkinsonian activity as monotherapy, and as additional therapy in patients with insufficient response to levodopa. Inpharma Wkly. 754, 6–7 (1990). https://doi.org/10.2165/00128413-199007540-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199007540-00014